Oncotarget

Reviews:

Targeting WNT5B and WNT10B in osteosarcoma

Gustavo A. Miranda-Carboni and Susan A. Krum _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:535-540. https://doi.org/10.18632/oncotarget.28617

Metrics: PDF 629 views  |   Full Text 2591 views  |   ?  


Abstract

Gustavo A. Miranda-Carboni1,2 and Susan A. Krum2,3

1 Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA

2 Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN 38163, USA

3 Department of Orthopaedic Surgery and Biomedical Engineering, University of Tennessee Health Science Center, Memphis, TN 38163, USA

Correspondence to:

Susan A. Krum, email: [email protected]

Keywords: WNT5B; WNT10B; WNT signaling; osteosarcoma

Received: June 24, 2024     Accepted: July 15, 2024     Published: August 02, 2024

Copyright: © 2024 Miranda-Carboni and Krum. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

WNT signaling regulates osteosarcoma proliferation. However, there is controversy in the field of osteosarcoma as to whether WNT signaling is pro- or anti-tumorigenic. WNT-targeting therapeutics, both activators and inhibitors, are compared. WNT5B, a β-catenin-independent ligand, and WNT10B, a β-catenin-dependent WNT ligand, are each expressed in osteosarcomas, but they are not expressed in the same tumors. Furthermore, WNT10B and WNT5B regulate different histological subtypes of osteosarcomas. Using WNT signaling modulators as therapeutics may depend on the WNT ligand and/or the activated signaling pathway.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28617